0.18
-10.00%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Rakovina Therapeutics
Its shares trade on TSX Venture under the ticker RKV.V. It has been listed since 7 February 2020.
Rakovina Therapeutics, Inc. focuses on the development of new cancer treatments based on novel DNA-damage response technologies. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2020-02-07. The firm is engaged in advancing cancer therapies based on deoxyribonucleic acid (DNA)-damage response technologies. The firm has a pipeline of DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials and obtain marketing approval for cancer therapeutics. The Company’s research programs include kt-2000, kt-3000 and kt-4000. The kt-2000 next generation PARP-inhibitors. The kt-3000 class drug candidates are rationally designed to overcome treatment resistance by selectively downregulating DNA double-strand (DSB) repair mechanisms while enhancing PARP inhibitor activity. The kt-4000 series lead candidates release a potent methylation agent causing damage to a tumor cell’s DNA while also inhibiting DNA-damage repair mechanisms to cancer cell death.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 7 Feb 2020
Leadership
Pay as last reported
- Mr. Jeffrey BachaExecutive Chairman of the Board, since 2021C$120,000
- Dr. Mads DaugaardPresident, Chief Scientific Officer
- Mr. Alfredo De LucreziaIndependent Non-Executive Vice Chairman of the Board, since 2019C$39,000
- Dr. David KideckelChief Financial Officer, Executive Director, since 2025
- Dr. John LanglandsChief Operating Officer
- Mr. Yevgeniy MeshcherekovDirector
- Dr. Dennis BrownIndependent DirectorC$35,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Rakovina Therapeutics focuses on DNA-damage response technologies for cancer treatments.
- kt-2000 is a next generation PARP-inhibitor in development.
- kt-3000 class drug candidates overcome treatment resistance by downregulating DNA repair mechanisms.
Weaknesses
- Rakovina Therapeutics has no drug candidates in human clinical trials yet.
- The company's pipeline includes kt-2000, kt-3000, and kt-4000.
- Rakovina Therapeutics has not obtained marketing approval for any cancer therapeutics.
Opportunities
- Rakovina Therapeutics aims to advance kt-2000, kt-3000, and kt-4000 into human clinical trials.
- The company's DNA-damage response inhibitors could address unmet needs in cancer therapy.
- Rakovina Therapeutics' research programs target multiple cancer treatment mechanisms.
Threats
- Rakovina Therapeutics faces competition from established cancer treatment companies.
- The company's success depends on regulatory approvals for its drug candidates.
- Rakovina Therapeutics must secure additional funding to advance its pipeline.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.